SNDX Syndax Pharmaceuticals Inc
Price (delayed)
$17.99
Market cap
$1.53B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.39
Enterprise value
$1.43B
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab,
Highlights
SNDX's debt is down by 46% YoY and by 19% from the previous quarter
The quick ratio has contracted by 23% YoY but it has grown by 18% from the previous quarter
SNDX's equity is down by 12% QoQ but it is up by 9% YoY
The net income has plunged by 65% YoY and by 10% from the previous quarter
The EPS has declined by 40% year-on-year and by 5% since the previous quarter
Key stats
What are the main financial stats of SNDX
Market
Valuations
Earnings
Shares outstanding
85.1M
Market cap
$1.53B
Enterprise value
$1.43B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.52
Price to sales (P/S)
438.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
407.54
Revenue
$3.5M
EBIT
-$263.85M
EBITDA
-$262.87M
Free cash flow
-$241.2M
Per share
Balance sheet
Liquidity
EPS
-$3.39
Free cash flow per share
-$2.83
Book value per share
$5.11
Revenue per share
$0.04
TBVPS
$5.59
Total assets
$476.95M
Total liabilities
$42.61M
Debt
$1.13M
Equity
$434.34M
Working capital
$403.58M
Debt to equity
0
Current ratio
10.5
Quick ratio
10.41
Net debt/EBITDA
0.4
Margins
Efficiency
Dividend
EBITDA margin
-7,510.6%
Gross margin
100%
Net margin
-7,545.2%
Operating margin
-8,228.3%
Return on assets
-52%
Return on equity
-57.4%
Return on invested capital
-85.3%
Return on capital employed
-60.7%
Return on sales
-7,538.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SNDX stock price
How has the Syndax Pharmaceuticals stock price performed over time
Intraday
-1.8%
1 week
-8.21%
1 month
-8.4%
1 year
4.05%
YTD
-16.75%
QTD
-12.37%
Financial performance
How have Syndax Pharmaceuticals's revenue and profit performed over time
Revenue
$3.5M
Gross profit
$3.5M
Operating income
-$287.99M
Net income
-$264.08M
Gross margin
100%
Net margin
-7,545.2%
The operating income has plunged by 67% YoY and by 9% from the previous quarter
The net income has plunged by 65% YoY and by 10% from the previous quarter
Growth
What is Syndax Pharmaceuticals's growth rate over time
Valuation
What is Syndax Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.52
P/S
438.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
407.54
The EPS has declined by 40% year-on-year and by 5% since the previous quarter
SNDX's equity is down by 12% QoQ but it is up by 9% YoY
SNDX's price to book (P/B) is 11% lower than its 5-year quarterly average of 4.0 but 5% higher than its last 4 quarters average of 3.4
Efficiency
How efficient is Syndax Pharmaceuticals business performance
The return on invested capital has dropped by 81% year-on-year and by 8% since the previous quarter
The company's return on equity fell by 47% YoY and by 8% QoQ
Syndax Pharmaceuticals's return on assets has decreased by 42% YoY and by 7% QoQ
Dividends
What is SNDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SNDX.
Financial health
How did Syndax Pharmaceuticals financials performed over time
The total liabilities has increased by 36% year-on-year but it has declined by 17% since the previous quarter
The quick ratio has contracted by 23% YoY but it has grown by 18% from the previous quarter
SNDX's debt is 100% less than its equity
The debt to equity has dropped by 100% year-on-year
SNDX's debt is down by 46% YoY and by 19% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.